Smith and Nephew to distribute SUPARTZ:
This article was originally published in Clinica
Smith & Nephew is to have exclusive marketing rights to Tokyo-based Seikagaku's hyaluronic acid product, SUPARTZ, under a ten-year agreement. Financial terms were not disclosed. S&N will have distribution rights in the US, Canada, Australia, South Africa, the UK and some other European countries. The product is injected into the knee joint to reduce pain from osteoarthritis. It also helps to improve joint mobility. SUPARTZ has received the CE mark and the company is awaiting approval from the US FDA. The Arthritis Foundation estimates that there are around 16 million osteoarthritis sufferers in the US.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.